Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose naproxen sodium + caffeine for postsurgical dental pain
2019-003513-33Phase 2
- Sponsor
- Bayer
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Aprol and caffeine in postoperative pain and odontalgia (4 arms), sponsored by Bayer. Primary endpoint: Sum of pain intensity difference over 8 hours (SPID0–8).
02
Drugs
Aprolcaffeine
03
Conditions
postoperative painodontalgia
Beyond the preview
Go deeper on 2019-003513-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003513-33.